Trial Profile
FREEDOM DR: An International, Multi-Center, 12-Week, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study Followed by a 12-Week Open-Label Extension Study to Assess the Efficacy, Safety, and Dose Response of UT-15C SR in Subjects With Pulmonary Hypertension
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms FREEDOM DR
- Sponsors United Therapeutics Corporation
- 25 Jun 2014 New trial record
- 29 Jan 2013
- 07 Jul 2009